Comparison of prostate-specific membrane antigen-based 18F-DCFBC PET/CT to conventional imaging modalities for detection of hormone-naïve and castration-resistant metastatic prostate cancer

Journal of Nuclear Medicine

Volumn 57, Issue 1, 2016, Pages 46-53

  Rowe, Steven P ^a   MacUra, Katarzyna J ^a   Ciarallo, Anthony ^a   Mena, Esther ^a   Blackford, Amanda ^a   Nadal, Rosa ^a   Antonarakis, Emmanuel S ^a   Eisenberger, Mario A ^a   Carducci, Michael A ^a   Ross, Ashley E ^a   Kantoff, Philip W ^b   Holt, Daniel P ^a   Dannals, Robert F ^a   Mease, Ronnie C ^a   Pomper, Martin G ^a   Cho, Steve Y ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Bone scan; Computed tomography; Metastatic prostate cancer; Positron emission tomography; Prostate specific membrane antigen

Indexed keywords

ABIRATERONE; CABAZITAXEL; DOCETAXEL; N [N (1,3 DICARBOXYPROPYL)CARBAMOYL] 4 FLUOROBENZYL LEVO CYSTEINE F 18; NELFINAVIR; PROSTATE SPECIFIC MEMBRANE ANTIGEN; RADIOISOTOPE; RADIUM 223; SIPULEUCEL T; TASQUINIMOD; TRACER; UNCLASSIFIED DRUG; VELIPARIB; CYSTEINE; GLUTAMATE CARBOXYPEPTIDASE II; GLUTAMATE CARBOXYPEPTIDASE II, HUMAN; MEMBRANE ANTIGEN; N-(N-((S)-1,3-DICARBOXYPROPYL)CARBAMOYL)-4-(18F)FLUOROBENZYL-L-CYSTEINE;

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BONE METASTASIS; BONE SCINTISCANNING; BRACHYTHERAPY; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL ARTICLE; COHORT ANALYSIS; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCED COMPUTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; EXTERNAL BEAM RADIOTHERAPY; HORMONE NAIVE PROSTATE CANCER; HUMAN; INTERMETHOD COMPARISON; LYMPH NODE METASTASIS; MALE; METASTASIS; MIDDLE AGED; PET-CT SCANNER; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; PROSTATECTOMY; SENSITIVITY ANALYSIS; STANDARD; VERY ELDERLY; VISCERAL METASTASIS; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; COMPARATIVE STUDY; DIAGNOSTIC IMAGING; METABOLISM; MULTIMODAL IMAGING; POSITRON EMISSION TOMOGRAPHY; PROCEDURES; X-RAY COMPUTED TOMOGRAPHY;

AGED; AGED, 80 AND OVER; ANTIGENS, SURFACE; CYSTEINE; GLUTAMATE CARBOXYPEPTIDASE II; HUMANS; MALE; MIDDLE AGED; MULTIMODAL IMAGING; POSITRON-EMISSION TOMOGRAPHY; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84958605968     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.115.163782     Document Type: Article

References (40)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64:9-29.
2. Bauman G, Belhocine T, Kovacs M, Ward A, Beheshti M, Rachinsky I. 18F-fluorocholine for prostate cancer imaging: a systematic review of the literature. Prostate Cancer Prostatic Dis. 2012;15:45-55.
3. Beheshti M, Treglia G, Zakavi SR, et al. Application of 11C-acetate positron-emission tomography (PET) imaging in prostate cancer: systematic review and metaanalysis of the literature. BJU Int. 2013;2013:13.
4. Evangelista L, Guttilla A, Zattoni F, Muzzio PC. Utility of choline positron emission tomography/computed tomography for lymph node involvement identification in intermediate-to high-risk prostate cancer: a systematic literature review and metaanalysis. Eur Urol. 2013;63:1040-1048.
5. Evangelista L, Zattoni F, Guttilla A, Saladini G, Colletti PM, Rubello D. Choline PET or PET/CT and biochemical relapse of prostate cancer: a systematic review and meta-analysis. Clin Nucl Med. 2013;38:305-314.
6. Fuccio C, Rubello D, Castellucci P, Marzola MC, Fanti S. Choline PET/CT for prostate cancer: main clinical applications. Eur J Radiol. 2011;80:e50-e56.
7. 18F-FDG, 18F-or 11C-acetate, and 18F-or 11Ccholine. J Nucl Med. 2011;52:81-89.
8. Mertens K, Slaets D, Lambert B, Acou M, De Vos F, Goethals I. PET with 18Flabelled choline-based tracers for tumour imaging: a review of the literature. Eur J Nucl Med Mol Imaging. 2010;37:2188-2193.
9. UmbehrMH, Muntener M, Hany T, Sulser T, BachmannLM. The role of 11C-choline and 18F-fluorocholine positron emission tomography (PET) and PET/CT in prostate cancer: a systematic review and meta-analysis. Eur Urol. 2013;64:106-117.
10. Schuster DM, Votaw JR, Nieh PT, et al. Initial experience with the radiotracer anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid with PET/CT in prostate carcinoma. J Nucl Med. 2007;48:56-63.
11. Schuster DM, Savir-Baruch B, Nieh PT, et al. Detection of recurrent prostate carcinoma with anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid PET/CT and 111In-capromab pendetide SPECT/CT. Radiology. 2011;259:852-861.
12. Mena E, Turkbey B, Mani H, et al. 11C-acetate PET/CT in localized prostate cancer: a study with MRI and histopathologic correlation. J Nucl Med. 2012;53:538-545.
13. Cho SY, Gage KL, Mease RC, et al. Biodistribution, tumor detection, and radiation dosimetry of 18F-DCFBC, a low-molecular-weight inhibitor of prostatespecific membrane antigen, in patients with metastatic prostate cancer. J Nucl Med. 2012;53:1883-1891.
14. Mease RC, Dusich CL, Foss CA, et al. N-[N-[(S)-1,3-dicarboxypropyl]carbamoyl]-4-[18F]fluorobenzyl-L-cysteine, [18F]DCFBC: a new imaging probe for prostate cancer. Clin Cancer Res. 2008;14:3036-3043.
15. Afshar-Oromieh A, Malcher A, Eder M, et al. PET imaging with a [68Ga]galliumlabelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl MedMol Imaging. 2013;40:486-495.
16. Afshar-Oromieh A, Avtzi E, Giesel FL, et al. The diagnostic value of PET/CT imaging with the 68Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2015;42:197-209.
17. Barrett JA, Coleman RE, Goldsmith SJ, et al. First-in-man evaluation of 2 highaffinity PSMA-avid small molecules for imaging prostate cancer. J Nucl Med. 2013;54:380-387.
18. Vallabhajosula S, Nikolopoulou A, Babich JW, et al. 99mTc-labeled small-molecule inhibitors of prostate-specific membrane antigen: pharmacokinetics and biodistribution studies in healthy subjects and patients with metastatic prostate cancer. J Nucl Med. 2014;55:1791-1798.
19. Tagawa ST, Milowsky MI, Morris M, et al. Phase II study of lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer. Clin Cancer Res. 2013;19:5182-5191.
20. 89Zr-labeled huJ591 engineered antibody fragments: the faster alternatives. Mol Pharm. 2014;11:3965-3973.
21. 89Zr-J591/prostate specific membrane antigen positron emission tomography in men with localized prostate cancer undergoing radical prostatectomy. J Urol. 2014;191:1439-1445.
22. Wieser G, Mansi R, Grosu AL, et al. Positron emission tomography (PET) imaging of prostate cancer with a gastrin releasing peptide receptor antagonist-from mice to men. Theranostics. 2014;4:412-419.
23. Lieberman BP, Ploessl K, Wang L, et al. PET imaging of glutaminolysis in tumors by 18F-(2S,4R)4-fluoroglutamine. J Nucl Med. 2011;52:1947-1955.
24. Venneti S, Dunphy MP, Zhang H, et al. Glutamine-based PET imaging facilitates enhanced metabolic evaluation of gliomas in vivo. Sci Transl Med. 2015;7:274ra17.
25. Sweat SD, Pacelli A, Murphy GP, Bostwick DG. Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases. Urology. 1998;52:637-640.
26. Chang SS, Reuter VE, Heston WD, Gaudin PB. Comparison of anti-prostatespecific membrane antigen antibodies and other immunomarkers in metastatic prostate carcinoma. Urology. 2001;57:1179-1183.
27. Wright GL Jr, Grob BM, Haley C, et al. Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology. 1996;48:326-334.
28. Evans MJ, Smith-Jones PM, Wongvipat J, et al. Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen. Proc Natl Acad Sci USA. 2011;108: 9578-9582.
29. Noss KR, Wolfe SA, Grimes SR. Upregulation of prostate specific membrane antigen/folate hydrolase transcription by an enhancer. Gene. 2002;285:247-256.
30. Perner S, Hofer MD, Kim R, et al. Prostate-specific membrane antigen expression as a predictor of prostate cancer progression. Hum Pathol. 2007;38: 696-701.
31. Ross JS, Sheehan CE, Fisher HA, et al. Correlation of primary tumor prostatespecific membrane antigen expression with disease recurrence in prostate cancer. Clin Cancer Res. 2003;9:6357-6362.
32. Rowe SP, Gage KL, Faraj SF, et al. 18F-DCFBC PET/CT for PSMA-based detection and characterization of primary prostate cancer. J Nucl Med. 2015;56: 1003-1010.
33. Kozikowski AP, Nan F, Conti P, et al. Design of remarkably simple, yet potent urea-based inhibitors of glutamate carboxypeptidase II (NAALADase). J Med Chem. 2001;44:298-301.
34. Holt DPRH, Mathews WB, Horti A, Mease R, Dannals RF. A semi-automated microwave chemistry system for complete radiosynthesis, purification, and formulation of F-18 radiotracers. J Label Compd Radiopharm. 2011;54.
35. Foss CA, Mease RC, Cho SY, Kim HJ, Pomper MG. GCPII imaging and cancer. Curr Med Chem. 2012;19:1346-1359.
36. Yao V, Berkman CE, Choi JK, O'Keefe DS, Bacich DJ. Expression of prostatespecific membrane antigen (PSMA), increases cell folate uptake and proliferation and suggests a novel role for PSMA in the uptake of the non-polyglutamated folate, folic acid. Prostate. 2010;70:305-316.
37. Yao V, Parwani A, Maier C, Heston WD, Bacich DJ. Moderate expression of prostate-specific membrane antigen, a tissue differentiation antigen and folate hydrolase, facilitates prostate carcinogenesis. Cancer Res. 2008;68: 9070-9077.
38. The R Foundation. R: A Language and Environment for Statistical Computing. The R Foundation website. https://www.r-project.org/. Updated August 2015. Accessed November 10, 2015.
39. Szabo Z, Mena E, Rowe SP, et al. Initial evaluation of [F]DCFPyL for prostate-Specific membrane antigen (PSMA)-targeted PET imaging of prostate cancer. Mol Imaging Biol. 2015;17:565-574.
40. Sanchez-Crespo A. Comparison of gallium-68 and fluorine-18 imaging characteristics in positron emission tomography. Appl Radiat Isot. 2013;76:55-62.